相关实验视频
Updated: Jul 19, 2025
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.9K
作为心力衰竭潜在治疗策略的ALKBH5抑制剂 - - 从基因表达特征分析推断得出的推断
Sumra Komal1, Atia Gohar2, Saad Althobaiti3
1Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Frontiers in cardiovascular medicine
|August 16, 2023
概括
新的基因标记物ALKBH5和KMT2E在心力衰竭 (HF) 中显著过度表达. 这项研究确定了针对ALKBH5的潜在治疗分子,用于HF管理.
科学领域:
- 分子生物学分子生物学
- 心血管研究的心血管研究.
- 基因组学就是基因组学.
背景情况:
- 心力衰竭 (HF) 是一种临床关键综合征,具有显著的全球发病率和死亡率.
- 尽管进行了广泛的研究,但对HF预后和管理的分子标记仍然不太了解.
- 识别新的分子标对于改善高频率治疗策略至关重要.
研究的目的:
- 识别与心力衰竭病理生理学相关的新型分子标记物.
- 调查mRNA脱甲基化和基因素修饰在高血压中所起的作用.
- 通过准已识别的标记物,发现用于HF管理的潜在治疗化合物.
主要方法:
- 使用in silico工具对失败和非失败的人类心脏样本进行全转录组分析.
- 在低毒细胞中使用定量PCR (qPCR) 和点点测试验验证基因表达.
- 虚拟查和分子对接以确定ALKBH5.5的潜在药物抑制剂.
主要成果:
- 在失败的心脏中,ALKBH5 (mRNA去甲基化) 和KMT2E (基因素修饰) 显著过度表达.
- 全球m6A水平在缺氧细胞中降低,与增加ALKBH5表达相关.
- 通过虚拟查,几种化合物被确定为ALKBH5的潜在抑制剂.
结论:
- ALKBH5和KMT2E代表了与心力衰竭病理生理学有关的新型分子标记物.
- ALKBH5在衰竭的心脏细胞中起着可能的作用,这表明它是潜在的治疗点.
- 该研究为开发HF管理的新治疗策略提供了基础.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:26Heart Failure Drugs: Inotropic Agents
622
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
622
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15